Valuation: StemRIM

Market Cap 18.68B 117M 101M 94.17M 86.2M 162M 11.24B 164M 1.11B 434M 5.65B 441M 432M P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 11.68B 73.5M 62.96M 58.91M 53.93M 101M 7.03B 103M 696M 271M 3.53B 276M 270M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
49.63%
Yield 2024 *
-
Yield 2025 -
1 day+0.56%
1 week+2.59%
Current month+19.80%
1 month+21.43%
3 months+21.84%
6 months+19.40%
Current year+35.74%
1 week 337
Extreme 337
368
1 month 280
Extreme 280
368
Current year 260
Extreme 260
368
1 year 246
Extreme 246
368
3 years 246
Extreme 246
881
5 years 246
Extreme 246
1,518
10 years 246
Extreme 246
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 2022-09-30
Chief Executive Officer 58 2023-10-24
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 2007-01-31
Director/Board Member 58 2019-02-28
Director/Board Member 54 2019-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+0.56%+2.59%+13.33%-58.97% 141M
+0.90%+3.80%+41.49%-0.78% 83.28B
+8.86%+129.20%+435.14%+24.85% 57.94B
-1.69%+23.30%-22.30%-36.29% 57.77B
-1.46%+0.19%-2.06%+30.50% 51.75B
+1.74%+4.43%+12.37%+169.64% 49.35B
+1.13%+3.31%+55.61%-17.57% 32.03B
+0.46%+6.37%+50.29%+97.27% 25.91B
+1.19%+9.17%+2.97%+230.86% 22.74B
-0.30%+4.45%+58.29%+118.84% 16.87B
Average +1.14%+18.68%+64.51%+55.84% 39.78B
Weighted average by Cap. +1.44%+24.97%+80.50%+46.33%

Financials

2024 2025
Net sales - -
Net income -2.02B -12.72M -10.9M -10.19M -9.33M -17.51M -1.22B -17.74M -120M -46.97M -611M -47.76M -46.72M -1.93B -12.13M -10.39M -9.73M -8.9M -16.71M -1.16B -16.93M -115M -44.81M -583M -45.56M -44.57M
Net Debt -8.41B -52.9M -45.32M -42.4M -38.81M -72.84M -5.06B -73.8M -501M -195M -2.54B -199M -194M -6.99B -43.99M -37.69M -35.26M -32.28M -60.58M -4.21B -61.38M -417M -162M -2.11B -165M -162M
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
-
Date Price Change Volume
26-08-21 ¥357.00 +0.56% 495,100
26-08-20 ¥355.00 +3.50% 383,200
26-08-19 ¥343.00 -1.44% 492,700
26-08-18 ¥348.00 0.00% 546,600
26-08-17 ¥348.00 0.00% 397,200
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4599 Stock